We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Nanoparticle Treatment Cures Bacterial Infection in Model

By LabMedica International staff writers
Posted on 24 Jul 2017
A novel approach for treating bacterial infections is based on the use of porous silicon nanoparticles to transport a combination of bactericidal peptides, which penetrate the cell membranes of Gram-negative bacteria and kill them with minimal unpleasant side effects.

In order to improve antibacterial delivery, investigators at the Massachusetts Institute of Technology (Cambridge, MA, USA) developed an anti-infective nanomaterial that utilized two strategies for localization: i) a biodegradable nanoparticle carrier to localize therapeutics within the tissue, and ii) a novel tandem peptide cargo to localize payload to bacterial membranes.

The first step was to screen a library of antibacterial peptides that combined membrane-localizing peptides with toxic peptides. More...
This screen identified a tandem peptide - the toxic peptide KLAKAK (lysine-leucine-alanine-lysine-alanine-lysine) and the transport peptide lactoferrin - that displayed synergy between the two domains and was able to kill Pseudomonas aeruginosa at sub-micromolar concentrations.

To apply this material to the lung, the tandem peptide was loaded into porous silicon nanoparticles (pSiNPs). Charged peptide payloads were loaded into the pores of the pSiNP at approximately 30% mass loading and approximately 90% loading efficiency using phosphonate surface chemistry.

The investigators reported in the July 12, 2017, online edition of the journal Advanced Materials that when delivered to the lungs of mice, this anti-infective nanomaterial was 30 times more effective at killing Pseudomonas aeruginosa than were the individual peptides administered without a carrier, and it was less toxic than the free peptides. Moreover, treatment of a lung infection of P. aeruginosa resulted in a large reduction in bacterial numbers and markedly improved survival compared to untreated mice.

This approach is modeled on a strategy that the investigators had previously used to deliver targeted cancer drugs. "There are a lot of similarities in the delivery challenges," said senior author Dr. Sangeeta Bhatia, professor of health sciences, technology and electrical engineering, and computer science at the Massachusetts Institute of Technology. "In infection, as in cancer, the name of the game is selectively killing something, using a drug that has potential side effects. We have adapted a lot of the same concepts from our cancer work, including boosting local concentration of the cargo and then making the cargo selectively interact with the target, which is now bacteria instead of a tumor."

Related Links:
Massachusetts Institute of Technology


Gold Member
Automatic Hematology Analyzer
DH-800 Series
Portable Electronic Pipette
Mini 96
New
Gold Member
Collection and Transport System
PurSafe Plus®
Gold Member
Auto Hematology Analyzer
DH-88CS [H]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: Private equity firms Blackstone and TPG have joined forces to acquire Hologic in a major healthcare deal (Photo courtesy of Hologic)

Hologic to be Acquired by Blackstone and TPG

Hologic (Marlborough, MA, USA) has entered into a definitive agreement to be acquired by funds managed by Blackstone (New York, NY, USA) and TPG (San Francisco, CA, USA) in a transaction valued at up to... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.